The global epigenetics industry is expected to reach
Dublin, June 16, 2022 (GLOBE NEWSWIRE) — The “Analysis report of the global epigenetics market size, share and trends by application (oncology and non-oncology), by product, by end-user, by Regional Outlook and Forecast, 2022-2028 Report” has been added to from ResearchAndMarkets.com offer.
The global epigenetics market size is expected to reach USD 2.9 billion by 2028, with the market growing at 14.6% CAGR during the forecast period.
Epigenetics is a field of genetics that examines changes in cellular and physiological characteristics produced by environmental or environmental variables that turn genes on and off and alter the cellular ability to read genes without being influenced by genotype changes. Although the underlying DNA or RNA sequence remains unchanged, epigenetics produces changes in an organism’s phenotype rather than its genotype. Epigenetic alterations are important for development because they are dynamic and change in response to environmental stimuli.
Epigenetics is a cutting-edge field that focuses on discovering and tracking phenotypic changes in genes caused by chromosomal changes without affecting DNA sequence. Although other uses are growing, this field is most often associated with cancer research. Growing institutional and governmental collaboration, as well as funding for the development of innovative disease detection and treatment methods, is expected to drive the demand for epigenetics, thereby propelling the market forward. For example, the University of Southampton and University Hospitals Southampton NHS Foundation Trust (UK) received US$1.57 million (£1 million) in February 2016 for genetics and genomics research in cancer and infectious diseases .
The increasing global prevalence of cancer, along with the increasing use of epigenetics in non-oncological diseases, are two significant factors driving the global epigenetics market. The number of cancer patients is expected to rise from 14.1 million in 2012 to 19.3 million by 2025, according to WHO projections. The number of new cancer cases in the United States rose from 1,685,210 in 2016 to 1,688,780 in 2017, according to the American Cancer Society.
Additionally, factors such as the rising prevalence of cancer have increased the funding for healthcare research and development, and the rise in non-oncology epigenetics applications is expected to help the market flourish further. According to Globocan 2020, 19,292,789 new cases of cancer of all kinds were recorded worldwide in 2020, with 9,958,133 cancer-related deaths. This global and widespread threat of cancer continues to be a significant driving force behind the development of new cancer therapies that facilitate risk assessment, early diagnosis and effective treatment monitoring.
COVID-19 Impact Analysis
Due to the importance of epigenetics in COVID-19 research, Covid has had a substantial impact on the growth of the epigenetics market. According to research published in Clinical Epigenetics in October 2020 titled “Epigenetic Involvement in Coronavirus Infection and Therapy,” epigenetic changes may play a key role in the emergence of coronavirus disease outcomes. Despite the fact that a variety of therapeutic alternatives are being investigated, further research is urgently needed to find a viable vaccine or safer chemotherapeutic drugs, including epigenetic treatments, to fight this viral pandemic and develop pre- and post-exposure COVID-19 prophylaxis.
Market Growth Factors:
Increased demand for DNA methylation
The epigenetics market is driven by DNA methylation, which is the covalent attachment of a methyl group to the cytosine ring, which inhibits transcription. Methylation-sensitive PCR is defined as bisulfite-sensitive modification followed by PCR (MSP). Variations of MSP include real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles. Quantitative methods for DNA methylation are currently available, including allele-specific bisulfite sequencing, southern-based approach, bisulfite pyrosequencing, and bisulfite PCR followed by MALDI-TOF MS. Improvements in technology facilitate the assessment of genome-wide locus-specific DNA methylation, which is driving the expansion of the market.
Increase in cancer incidence
The number of people diagnosed with cancer has increased dramatically all over the world. The number of cancer patients is expected to rise from 14.1 million in 2012 to 19.3 million by 2025, according to WHO projections. Cancer is the second leading cause of death in the United States, accounting for approximately one in four deaths. According to the American Cancer Society, the number of new cancer cases in the United States is expected to increase from 1,685,210 in 2016 to 1,688,780 in 2017, while the total number of cancer-related deaths is expected to increase from 595,690 to 600. 920 during the same period. period of time.
Marketing Restriction Factor:
The massive cost of instruments and the high need for standardization and clinical validation
Epigenetics research instruments are expensive due to their extensive features and functions. Illumina’s NovaSeq 5000 and 6000 sequencers, for example, were released in January 2017 and cost $850,000 and $985,000, respectively. The total cost of ownership is increased by maintenance and a series of other indirect expenses, such as samples and consumables. Consequently, many healthcare institutions are not quick to adopt these instruments. Pharmaceutical companies and research institutes need many of these systems. As a result, large sums of money will be needed to purchase a number of high-priced genomic devices. End-users with tight budgets, such as university research labs, find it difficult to afford such systems.
Main topics covered:
Chapter 1. Market Scope and Methodology
Chapter 2. Market Overview
18.104.22.168 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market constraints
Chapter 3. Competitive Analysis – Global
3.1 Cardinal matrix
3.2 Recent Industry-Wide Strategic Developments
3.2.1 Partnerships, collaborations and agreements
3.2.2 Product launches and product extensions
3.2.3 Acquisitions and mergers
3.3 Main winning strategies
3.3.1 Key Primary Strategies: Percentage Breakdown (2018-2022)
3.3.2 Key Strategic Movement: (Partnerships, Collaborations and Agreements: 2018, April – 2021, December) Key Players
Chapter 4. Global Epigenetics Market by Application
4.1 Global Oncology Market by Region
4.2 Global Non-Oncology Drugs Market by Region
Chapter 5. Global Epigenetics Market by Product
5.1 Global Repair Kits Market by Region
5.2 Global Reagents Market by Region
5.3 Global Enzymes Market by Region
5.4 Global Instrumentation Market by Region
Chapter 6. Global Epigenetics Market by End User
6.1 Global Pharmaceuticals and Biotechnology Companies Market by Region
6.2 Global Academic and Research Institutes Market by Region
6.3 Global Contract Research Organization Market by Region
Chapter 7. Global Epigenetics Market by Region
Chapter 8. Business Profiles
8.1 Abcam plc
8.1.1 Company Overview
8.1.2 Financial analysis
8.1.3 Sectoral and regional analysis
8.1.4 Research & Development expenses
8.1.5 Strategies and recent developments:
22.214.171.124 Partnerships, collaborations and agreements:
126.96.36.199 Acquisition and merger:
8.2 Agilent Technologies, Inc.
8.2.1 Company overview
8.2.2 Financial analysis
8.2.3 Sectoral and regional analysis
8.2.4 Research and development costs
8.2.5 Strategies and recent developments:
188.8.131.52 Partnerships, collaborations and agreements:
184.108.40.206 Acquisition and merger:
8.3 Hologic, Inc.
8.3.1 Company Overview
8.3.2 Financial analysis
8.3.3 Sectoral and regional analysis
8.3.4 Research and development costs
8.3.5 Strategies and recent developments:
220.127.116.11 Acquisition and merger:
8.4 Illumina, Inc.
8.4.1 Company Overview
8.4.2 Financial analysis
8.4.3 Regional Analysis
8.4.4 Research and development costs
8.4.5 Strategies and recent developments:
18.104.22.168 Partnerships, collaborations and agreements:
8.5 Merck Group (Merck Millipore)
8.5.1 Company Overview
8.5.2 Financial analysis
8.5.3 Sectoral and regional analysis
8.5.4 Research and development costs
8.6 PerkinElmer, Inc.
8.6.1 Company Overview
8.6.2 Financial analysis
8.6.3 Sectoral and regional analysis
8.6.4 Research and development costs
8.6.5 Strategies and recent developments:
22.214.171.124 Partnerships, collaborations and agreements:
126.96.36.199 Product launches and product extensions:
188.8.131.52 Acquisition and merger:
8.7 Qiagen AG
8.7.1 Company Overview
8.7.2 Financial analysis
8.7.3 Regional Analysis
8.7.4 Research and development costs
8.7.5 Strategies and recent developments:
184.108.40.206 Partnerships, collaborations and agreements:
8.8 Thermo Fisher Scientific, Inc.
8.8.1 Company Overview
8.8.2 Financial analysis
8.8.3 Sectoral and regional analysis
8.8.4 Research and development costs
8.8.5 Strategies and recent developments:
220.127.116.11 Partnerships, collaborations and agreements:
8.9 Zymo Search
8.9.1 Company Overview
8.9.2 Strategies and recent developments:
18.104.22.168 Partnerships, collaborations and agreements:
8.10. Active Pattern, Inc.
8.10.1 Company Overview
8.10.2 Strategies and recent developments:
22.214.171.124 Partnerships, collaborations and agreements:
126.96.36.199 Acquisition and merger:
For more information about this report visit https://www.researchandmarkets.com/r/jxe7gw
Comments are closed.